Novo Nordisk Losing Its Sugar High?

Posted on April 30, 2012 at 16:15 PM EDT

The world’s largest insulin maker missed aggressive estimates by an eyelash, and investors sold off heavily. The long-term story is still undeniable, but it has more room to pull back to a better buy-in price, writes MoneyShow’s Jim Jubak , also of Jubak’s Picks .

Related Stocks:

Arena Pharmaceuticals, Inc. Merck & Co., Inc. Novo Nordisk A/S ADS Orexigen Therapeutics, Inc. Pfizer, Inc. Vivus, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates

More InvestorPlace Features